Literature DB >> 5127083

Methotrexate pharmacokinetics.

K B Bischoff, R L Dedrick, D S Zaharko, J A Longstreth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5127083     DOI： 10.1002/jps.2600600803

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  122 in total

1.  A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics.

Authors:  R E Oliver; A F Jones; M Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver.

Authors:  S Kanamitsu; K Ito; Y Sugiyama
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

3.  Do you need a pharmacokinetic model, and, if so, which one?

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

4.  Distribution of HEOD (dieldrin) in mammals: II. some applications of the preliminary model.

Authors:  F T Lindstrom; J W Gillett; S E Rodecap
Journal:  Arch Environ Contam Toxicol       Date:  1975       Impact factor: 2.804

5.  A dispersion model for cellular signal transduction cascades.

Authors:  Murali Ramanathan
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

6.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

7.  Pharmacokinetic modeling of the dogfish shark (Squalus acanthias): distribution and urinary and biliary excretion of phenol red and its glucuronide.

Authors:  P M Bungay; R L Dedrick; A M Guarino
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

8.  First-pass effect of cis-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)- cyclohexyl)-benzamide (U-54494) in rats--a model with multiple cannulas for investigation of gastrointestinal and hepatic metabolism.

Authors:  W Z Zhong; M G Williams; K J Cook; T L VandeGiessen; B W Jones; K E Rousch
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

9.  Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.

Authors:  Yuansheng Zhao; Zhe-Yi Hu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

10.  'MacDope': a simulation of drug disposition in the human body: applications in clinical pharmacokinetics.

Authors:  R Bloch; G Sweeney; K Ahmed; C J Dickinson; D Ingram
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.